

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Equality and health inequality impact assessment**

**Brentuximab vedotin in combination for untreated advanced classical  
Hodgkin lymphoma [ID6437]**

**Scoping**

- 1 Have any potential equality issues been identified during the scoping process? If so, what are they?**

No equality issues were raised by stakeholders.

- 2 Have any potential health inequality issues been identified during the scoping process? If so, what are they?**

No health inequality issues were raised by stakeholders.

- 3 What is the preliminary view as to what extent the committee needs to address the potential issues set out in questions 1 and 2?**

N/A

- 4 Has any change to the draft scope been agreed to highlight the potential equality or health inequality issues set out in questions 1 and 2 following the scope consultation?**

No changes to the scope have been made.

- 5 Has the stakeholder list been updated as a result of additional equality or health inequality issues identified during the scoping process?**

No additional stakeholders have been identified.

**Approved by senior responsible officer:** Lorna Dunning

**Date:** 05/06/2026